Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $54 Billion by 2030
The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$30.4 Billion in the year 2023, is expected to reach US$54 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 7.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $7.9 Billion, While China is Forecast to Grow at 12.9% CAGR
The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$7.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 7.5% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.9 Billion by the year 2030.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook